Health Wonk Review: The Early Bird Catches the Worm Spring Edition

Tradition is important, and it has become a Health Wonk Review tradition to have a theme for each edition. Usually, the edition’s host organizes content by topic or finds some overarching theme to propel the issue forward.

early birdIn the spirit of innovation, the entries this week are organized according to the order in which they arrived in my inbox. This relieves me, as the host, of the awesome responsibility of finding a compelling theme. First in, Dr. Bradley Flansbaum.

The Early Bird

 Dr. Bradley Flansbaum offers a birds-eye view of the physician relationship with the pharmaceutical industry at The Hospital Leader: the Official blog of the Society of Hospital Medicine. Dr. Flansbaum details his interactions with the pharmaceutical industry – from a young hospitalist receiving speaker’s honoraria to a pharma-sponsored researcher. If you want to know about the relationship between the pharmaceutical industry and the medical profession, this is a good primer. Dr. Flansbaum has chosen to opt out of all relationships with pharma, and he is eloquent in explaining his professional position. At the risk of taking the suspense out of his story, in part, here is his conclusion:

“Remember why we call industry, industry. It’s a business. They sell, and we buy. That’s my message so do with it what you will.”

Healthcare Economist Asks “Is P4P doomed to fail?”

 The way pay-for-performance and quality incentive programs are currently structured, the conclusion one draws from Jason Shafrin’s question is, “Yes, P4P is doomed to fail.”  Jason bases his discussion on a referenced article in Health Economics that calls out a “fundamental design flaw in P4P design” which is, simply, a provider chasing too many quality metrics that result in rewarding competing measures. For providers and health care organizations looking to be reimbursed based on this model, the ensuing confusion can be hazardous to your patients’ health and the health of your bonus payment. Read the detail at Healthcare Economist.

Tracking ACA Enrollments: Figuring Out How Many Grandfathered/Grandmothered Plan Are Still Around

In this week’s entry, Charles Gaba of ACASignups.net gives us a breakdown of a tally of Grandfathered and Grandmothered plans in the individual market. He did, in his own words, a “back of the envelope” calculation and, with input from Louise Norris of healthinsurance.org, came up with an estimate of those old plans still hanging around. Charles says, “My Conclusion? There should be roughly 1 million people still enrolled in Grandfathered policies and perhaps 1.5 million in Transitional/Grandmothered plans today.” If you want to know the difference between Grandfathered and Grandmothered health care plans and the detail, click here.

Dare Roy Poses Suggest: Healthcare Leaders Should Come From Healthcare

Roy discusses a New England Journal of Medicine article describing “Immersion Day” during which members of the board of a non-profit hospital system who had no healthcare background were given a one-day exposure to life in the hospital. Roy Poses poses (sorry, I couldn’t help myself) an interesting hypothesis: “True health care reform would put more health care professionals back in control of health care, or failing that, would at least promote leadership by people with some knowledge of health care who would support health care values and would be willing to be accountable for doing so.” Read the detail about the NEJM article here.

 ObamaCare Wear: Gasoline Pants

Hank Stern’s InsureBlog is on top of the dish on ObamaCare. Blogger Mike Feehan writes this week that we have more bad news about the ACA. ObamaCare Co-ops are going the way of the dodo bird, according to Mike. In fact, I can’t improve on Mike’s description of the status quo, so here it is, in his own words: “As Nipsy Russell might have observed, the Obama administration’s health policy is running thru Hell in gasoline pants.” Read More Bad News About ObamaCare Co-Ops – Part CCIX – at InsureBlog.

 Health Plans Need to Consider the UX

Just as Apple figured out that computer users needed an intuitive interface to finally integrate computing into their daily lives, Joe Paduda of Health Strategy Associates says that the health plans that figure out how to give their members a good user experience will be winners. “Members do NOT want to wade thru fine print stuffed with SAT-test words and jargon that’s murky at best. Blaming the consumer for misunderstanding a benefit plan is just nuts; write the plan so it’s understandable for everyone” Read more at JoePaduda.com.

California Is the Harbinger of Things to Come

California often leads the way in trends that work their way across the country. Anthony Wright at Health Access Blog writes out of the state capitol in Sacramento from Health Access California where he and co-blogger Bethany Snyder tell us “Covered California produced a report about potential 1332 waivers, and gave a greenlight to one proposal to allow undocumented Californians to buy into the exchange with their own money.” Yes, insurance is governed at the state level, but keep your eye on California’s move to allow undocumented people to buy into the healthcare system and the implications it could have for the future of health insurance. Read Opening Up Covered California here.

The CMS Innovation Center and Next Generation ACOs

Writing for Health Affairs, Chris Dawe, Nico Lewine and Mike Miesen discuss the recent CMS Innovation Center announcement saying ACOs can share in 100 percent of the savings they create for the payer’s largest book of business, theNext Generation ACO. In Today’s Most Attractive National ACO Model is Offered By…CMS, the authors write, “Would-be Next Gen ACO participants must grapple with two primary hurdles: risk exposure and a closing decision window.” Read more about the tension created by being exposed for full risk for spending in excess of targets and opportunities to enjoy capturing savings at the Health Affairs blog.

Another Medicare Pilot: Medicare Comprehensive Primary Care

If you’ve read this far, you know that Dr. Jaan Sidorov is not the only HWR contributor this week who wonders if government should get out of the way and let healthcare do its job of caring for patients. In this entry at Disease Management Care Blog , Dr. Sidorov explains that Medicare has just launched a multi-year primary care initiative aimed at improving care, but that might not be as good as it sounds. Dr. Sidorov tells us that it is based on a two-year-old pilot that hasn’t shown improvement in costs or quality. He asks, “Should CMS get out of the care management game and let others handle the work of caring for populations with chronic conditions?”

Lack of Transparency or Just Plain Greed?

David Williams at Health Business Blog writes about healthcare’s version of the military’s $10,000 toilet seat: in this case, a $427 hospital charge is reimbursed at $22. He wonders what could be wrong. Is the hospital overbilling to begin with? Is the health insurance company underpaying? Or both? In Urgent Care Billing: Eyebrows Raised , David discusses the implications of this type of billing/reimbursement discrepancy.

And Finally, A Little Education from Worker’s Comp Insider

Julie Ferguson takes time to educate about occupational medicine and its unique place in healthcare. At Workers’ Comp Insider, Julie writes about how occupational medicine differs from other specialties, and she offers an informative video, “Introduction to Occupational and Environmental Medicine (OEM)”. Check out this training at Workers’ Comp Insider here.

Blabbin’ with the Wonkers at Health Wonk Review On Air with David Harlow

If our biweekly dose of health policy leaves you wanting even more detail about things like QALYs and risk corridors, please join us live, online, every other Tuesday for Health Wonk Review On Air with David Harlow. David is joined by other HWR contributors to discuss details of the most recent edition and whatever else is on their minds health policy-wise.

Blab is interactive, so it is a good place to ask questions and join the discussion. If you miss the session, you will be able to view the recording later. David posts the link at HealthBlawg.com.

 The next edition of Health Wonk Review On Air Blab is Tuesday, April 26 from 1 to 1:30 p.m. Eastern.  

 

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, elearning, health economics, health insurance, health policy, health reform, healthcare marketing, pharmaceutical marketing, pharmaceutical sales, training | 7 Comments

A Presidential Politics-free Health Wonk Review

Okay, people, it’s safe to come out now. Jaan Sidorov of The Population Health Blog has delivered a presidential-politics free edition of Health Wonk Review.

I’m hosting the next edition in two weeks, so this may be a short reprieve. Enjoy it!

For those who just can’t get enough of Health Wonk Review, we have great news. You can now enjoy some of the regulars live online every Tuesday at 1 p.m. Eastern on Blab. That’s right. We’ve started a weekly Blab confab. If you don’t know Blab, it is audio and video conversation where anyone can log in with a Twitter account and participate. You just need to download the Blab app to join the conversation.

Here’s the official press release from the head office:

Please join us for a new multimedia experience (video conversation and text chat), Health Wonk Review On Air With HealthBlawg next Tuesday, April 12, at 1 pm ET for half an hour. It’s a Blab; you’ll need a Twitter account to sign up and log in. Join us live, or watch the replay here later if you can’t make it.

 

 

 

 

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, consumer health apps, electronic patient records, health economics, health insurance, health IT, health policy, health reform, healthcare marketing, pharmaceutical marketing | Leave a comment

Behavior Change Driving Digital Health is Bubbling Up from the Bottom

This week marks one month since ePharma Summit 2016 opened and closed. It’s a good time to reflect on a final takeaway from the conference and close my notebook.

Clearly, there is more grand thinking about the future and emphasis on the promise of digital health at this point than in the celebration of successes. But that isn’t to say there aren’t a few current successes and some projects underway that will start to bear fruit even as I write this.

The most important aspect of digital health that I learned at the Summit was that patients are truly at the center of any advances in the use of healthcare technology to achieve lower cost, higher quality and improved outcomes. After all, it’s the patients who need answers who are behind the rapid uptake  of any promising health or wellness application that might offer hope, support, and solid answers.

Stupid Cancer Show founder Matthew Zachary said emphatically he has legions of Millennials with cancer using apps and participating in peer support who freely offer their information for healthcare professionals who can use it to advance a cure. It’s there for the taking, and it is being offered enthusiastically.

Another informational session featured the developers and founders of GI Health, an app that helps diagnose and support patients who have GI symptoms so they can provide accurate and potentially life-saving information to their gastroenterologists.

On the marketing side, another app tracks physician online interactions to help pharmaceutical companies get product information to prescribers at the point of making treatment decisions.

The bottom line here is that there are plenty of players from the patient, provider and payer worlds who already have their heads in the game. Expect any moment that this 24/7 interactivity with health information will reach critical mass and change the whole game of caring for patients.

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, consumer health apps, electronic patient records, health economics, health IT, health policy, health reform, healthcare change management, healthcare marketing, pharmaceutical marketing, pharmaceutical sales | 1 Comment

Healthcare Industry: World’s Largest Hairball?

Insight from WEGO CEO Jack Barrette and REVOLUTION CEO Steve Case

Epharma Summit 2016 has been over for two weeks, but the ideas generated by exciting thinkers, disruptors and innovators are still burning holes in my notebook.

Upon reflection, themes that continue to reverberate are the slow pace of the healthcare industry and particularly the conservative pharmaceutical industry playing against the tension of the magnetic pull of the future that is dislodging old ways…one way or another.

In a panel discussion “Pharma and The Third Wave of the Internet,” CEO of WEGO Jack Barrette told attendees,  “You are working in large organizations trying to move an industry that has been described as the world’s largest hairball.”

Panelist Steve Case, CEO Revolution and Founder of AOL, said we are entering the Third Wave of the internet. During the First Wave, the internet was being built between 1985 to 2000. From 2000 until today, we are just leaving the Second Wave where software and apps drove the growth and utility of the internet. The Third Wave will be about using the power of the internet to solve social problems and make “larger plays,” Case said.

“How do you improve food, health? It’s a broader play, a harder play, it takes more engagement from government because those industries are more highly regulated. It will be more about partnerships, policy, and perseverance. The internet wouldn’t happen without partnerships.”

Creative marketing ideas and customer-centric digital health are coming up against highly regulated healthcare, and particularly the pharmaceutical industry where not just the products – but the sales and marketing of those products – are tightly monitored and controlled.

Ideas follow where the dollars are spent, and most presenters and attendees at the ePharma conference agreed that few pharma dollars are dedicated to digital health initiatives partly because of fear of a new medium but also because digital dollars are often “stolen” from budgets dedicated for traditional sales and marketing initiatives. As the value of patient engagement using all-on, all-the-time digital tools becomes clearer, those dollars will start to move into more targeted campaigns.

Case said, “Some of these things just take awhile. The transition from TV to a more digital way, it is happening. When I watch TV and see an ad for drug that seems like it has narrow appeal, I wonder if that makes sense. Budgets should shift from (TV) to (digital marketing), but it will take time to happen.”

What is Case’s advice for people advocating for forging into the future inside a large organization? “Create a sense of possibility and momentum in a balanced way. Don’t come off as a crazy person looking too far in the future but provide clarity as to where this is going. Create a culture of possibility. Startups have a culture of experimentation and taking risk and shots on goal. Companies de-risk until it’s all about process and risk mitigation. But it’s not all about keeping bad things from happening. It’s tricky. In order to get an initiative supported, you need clarity about what will happen, but it is by definition guess work.

“One step at a time, momentum begets momentum. Get some traction, some initial beachhead. Accelerate the adoption and that will facilitate partnerships. Doing it together makes more sense than doing it separately. There is an African proverb: Go quickly, go alone; but go far, go together. That is the core idea of Third Wave,” he said.

 Pfizer VP Head of Digital Strategy and Data Innovation Judy Sewards echoed his optimism and caution, “If the future was easy or clear, we’d be activating it right now. But we are only just beginning the digital health revolution,”

 

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, consumer health apps, electronic patient records, health economics, health IT, health policy, health reform, healthcare marketing, pharmaceutical marketing | 2 Comments

Health Wonk Review: Ahhhh, Wake Up and Smell the…Fascism???

David Williams of The Health Business Group regales readers with Tales of Trump this week in his Health Wonk Review. Thank you, David! Read it herefascism.

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in health economics, health insurance, health IT, health policy, health reform | Leave a comment

Talking Past Each Other: Patient Engagement is More Than a Slogan

By Peggy Salvatore

This is one of a series of blogs posted out of the ePharma Summit 2016 where pharmaceutical marketing folks talked tech for three days.

The future is here. We just need to recognize it and start using it for the good of patients. The technology available today allows the healthcare industry to stop talking at patients, or talking past patients, and engage them in meaningful conversations.

It is at the intersection of patients, the providers who care for them and the payers who have to manage the finances to pay for it all where technology will integrate these powerful forces. There was a fundamental frustration you could feel from the futurists at ePharma Summit 2016 that they are dragging a reluctant healthcare sector along to make this future that is now, actually fulfill its promise now.

Vendors had exciting innovations. More on a few of those in the next blog. The issue that calls out for immediate attention, though, is the nexus of and reason for all the efforts and stakeholders at the table – the patients we need to engage. Those patients are us.

Co-founder and CEO of StartUp Health Steven Krein said, “We are all part of this in a way no other industry is. If we aren’t personally, somebody in our family is a patient.”

As an industry, how quickly those of us in pharma can get caught up in the sales numbers, the marketing strategy and the fun techie gadgets and forget that the patient is the whole point of why we are in this industry. When you scratch a healthcare professional – no matter whether a doctor, nurse, marketing executive or pharma sales rep – they will tell you they are in it because they care about a disease, a patient, a cure.

As founder of The Stupid Cancer Show, Matthew Zacchary, said in his powerful presentation to the industry, “The humanity you stand for can’t get lost in this. You guys and your kids get cancer too. We’re all patients, we’re all humans.”

Yes, we’re all human and we’re all patients. And technology can help us make those personal connections that drive our industry and our reason for being.

But how quickly we can forget, even temporarily. And it was one of those lapses that particularly dinged our reputation with patients who were present at ePharma Summit 2016.

 

Patient blogger Kristin Coppens brought all our attention snapping back to the reason we are all in business. She reminds us why we care. She blogged about some insensitivity to patients at the event, and it is something we all need to be aware of as we make sure that when we talk about Patient Engagement, Patient Experience and The Patient Journey, we remember what it means.

 

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, consumer health apps, electronic patient records, health economics, health insurance, health IT, health policy, health reform, healthcare marketing, pharmaceutical marketing, pharmaceutical sales, training | Leave a comment

Healthcare Reform: The Path Forward

IMG_2529-225x300Louise Norris shows us in this week’s Health Wonk Review that while the ACA is a done deal, it isn’t over. Click here to read more.

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, electronic patient records, health economics, health insurance, health IT, health policy, health reform, healthcare marketing, pharmaceutical marketing | Leave a comment

Digital Health Holds the Promise of Serving the “Underserved”

By Peggy Salvatore

This is the eighth entry in a series of blogs for ePharma Summit 2016 to explore ways the pharmaceutical industry can maximize the promise of digital health.

A report put out by the California Health Care Foundation  last week chronicled the promise of digital health holding the key to holding down costs for low-income patients with chronic conditions. After all, it is the poor, those with poor literacy and health literacy, who are often the ones with the highest rate of chronic disease – and the highest cost – to the healthcare system.

Who pays? For patients who fit this description, it is often the states and federal government who end up footing the bill for medications, emergency department care (because they sometimes don’t have a home at all, let alone a medical home) and inpatient stays. The study states:

Some 90 million Americans have multiple chronic conditions (MCCs), with the prevalence of MCCs highest among people with the lowest incomes. Each additional chronic disease increases a person’s risk of adverse drug events, higher out-of-pocket expenses, impaired functional status, hospitalization, and mortality. Two-thirds of health spending is associated with patients managing MCCs. (p.3)

A series of pilot programs have shown that even the poorest of the poor in unstable living situations often have a cell phone or even a smart phone, and Internet access at a computer. With just those tools, a few low-cost, high-touch digital outreach programs have moved the needle with medication compliance, attending appointments and maintaining health regimens recommended by their providers.

Here are a few highlights from this February 2016 CHCF study which surveyed global healthcare leaders:

  • Digital solutions use texting, customize language and communication style to the audience, uses portals, kiosks, video, telephone and cable, combines medical and social services, leverages a trusted human and collects data passively.
  • One-half of low-income adults own a smartphone and 84% own a cell phone. Customized text messaging bolstered appointment adherence by 40% and medication adherence by 12%. One successful test program has been expanded to Medicaid care management programs in New York.
  • Text4baby is a program in both English and Spanish that messages labor signs and symptoms, birth-defect prevention, prenatal care, urgent alerts, developmental milestones, immunizations, nutrition, safety and more. It also connects users to Medicaid and the CHIP program.
  • Meducation targets community health centers and translates medication and discharge instructions into 18 languages as well as provides visual instructions.
  • Kaiser Permanente implemented KP HealthConnect by mining retrospective data in the EHR and using HEDIS data sets to use electronic messaging to bolster outcomes for black patients managing diabetes and heart disease.
  • In a North Philadelphia grocery store in a low-income area of the city, one kiosk with behavioral health information encourages people to get “a check-up from the neck up”.

Some programs leverage relationships with faith-based initiatives, federally qualified health centers and university programs. The promise of digital health to help, diagnose, treat and manage diseases and common conditions (like pregnancy!) are only limited to our imagination.

With the desire to serve those who cannot afford and do not have regular access to healthcare, and the limitations of state and federal budgets to do so, digital health solutions can bridge the gap between poor health outcomes and managing high-risk populations.

 

 

 

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in consumer health apps, elearning, electronic patient records, health economics, health insurance, health IT, health IT training, health policy, health reform, healthcare change management, healthcare marketing | 1 Comment

Why Digital Health Is About Survival

This is the seventh entry in a series of blogs for ePharma Summit 2016 to explore ways the pharmaceutical industry can maximize the promise of digital health.

Whether it is data collection in the electronic patient record, information in the claims data base or monitoring of patient biometrics, data analysis and interpretation will be the lifeblood of healthcare organizations.

That lifeblood represents two critical elements 1) treatment delivered to the patient based on best practices and 2) quality care that supports value-based payment.

Simply put, for money to change hands in the future, you will need to show you’ve earned it using data. With public attention on drug costs, particularly after the Turing Pharmaceutical debacle where it took the price of a a toxoplasmosis drug from $13.50 to $750 a pill, biopharmaceuticals are under just as much pressure as anyone else to prove they are worth the price.

Novartis has stepped out in front of this parade by cutting outcomes-based pricing deals with Cigna and Aetna. The industry has been having discussion about outcomes-based pricing for a long time, but it is notoriously hard to determine exactly what to measure, and under what circumstances, to prove your – case. With better data and patient monitoring, pharma believes it has the tools – or soon will – to begin making these deals real.

The title of an article in mobihealthnews last week toplines the terms: Norvartis signs Aetna, Cigna for pay-for-performance drug deal, but not remote monitoring yet.

According to mobihealthnews.com, last fall when Novartis first mentioned how the deal would be structured, it told the Wall Street Journal that is was looking into remote monitoring and other digital health monitoring avenues to measure the drug’s performance, including possibly bundling devices with the drug, to support pricing. For now, it appears that part of the plan is on hold.

But the fact that the plan was well developed means that patient data – not just data in the patient record but biometric monitoring – is going to be part of pay-for-performance initiatives in the future.

So, if you think that exchanging digital information among patients, providers and payers, and the resultant data collection and tracking, is just nice to have for the cutting-edginess of it, do think again. The day is closer than it appears in your mirror when a mix of the digital assets available to healthcare will figure prominently in payment and reimbursement of all sorts.

Got value? Prove it.

 

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, consumer health apps, electronic patient records, health economics, health insurance, health IT, health reform, healthcare change management, healthcare marketing, pharmaceutical marketing, pharmaceutical sales | Leave a comment

Money Changes Everything Edition of Health Wonk Review

health-wonk-review-money-changes-everything-1560x816Steve Anderson is seeing green at MedicareResources.org this week for his compilation of health wonkery. Read this week’s Money Changes Everything edition here.

facebooktwittergoogle_pluslinkedinmailfacebooktwittergoogle_pluslinkedinmail
Posted in biotechnology, consumer health apps, electronic patient records, health economics, health insurance, health IT, health IT training, health policy, health reform, healthcare change management, healthcare marketing, pharmaceutical marketing, pharmaceutical sales | Leave a comment